News – Page 1021 – Endpoints News

Eyes on China stocks: Loncar loads new ETF with his picks for most promising biotechs on HKEX and Nasdaq

7 years ago

Back in business after a spell in limbo, Ironshore says it has raised $143M for ADHD drug rollout

7 years ago

The biotech mood at the halfway mark of 2018? Boisterous, focusing more attention on China and looking for ...

7 years ago

Looking to carve away market share from Gilead, ViiV and J&J score positive PhIII data for a monthly, 2-drug HIV ...

7 years ago

One more gig: Steven Paul decides to extend a 35-year track record with one last shot at a big development program

7 years ago

An exodus of top Gilead execs continues as newly named CMO Andrew Cheng heads for the exit

7 years ago

Billionaire-backed Juvenescence spins out anti-aging, AI startup Napa Therapeutics

7 years ago

Gilead loses key patent claims for Sovaldi in China, opening door to earlier generic entry

7 years ago

Acorda CTO Batycky is jumping ship to run a biotech; Motif gets a PDUFA date

7 years ago

Ex-Pfizer exec Geno Germano joins nanoparticle startup Elucida Oncology as CEO

7 years ago

Rogerio Vivaldi jumps from Bioverativ buyout to leading Flagship-seeded Sigilon's Holy Grail pursuit

7 years ago

Biogen’s big breakthrough drug Spinraza runs into a barrier as NICE turns thumbs down on reimbursement

7 years ago

Realm Therapeutics shares crater — again — on a failed PhII atopic dermatitis study

7 years ago

CEO interrupted: Novartis chief Narasimhan looks to new ethics czar to clean up after the lingering Cohen mess

7 years ago

Bayer targets COPD in a new discovery alliance with Haplogen, Evotec

7 years ago

Pfizer Oncology loses its CMO to Allergan as cancer exec Charles Hugh-Jones makes a career leap

7 years ago

After insider trading scandal, US congressman drops campaign — but stays on the ballot; Junshi Biosciences applies ...

7 years ago

Mustang Bio ventures into gene therapy, licensing 'bubble boy disease' treatment from St. Jude

7 years ago

Vertex’s fight club rule: Block new treatments to cystic fibrosis patients until Orkambi is reimbursed properly

7 years ago

FDA drafts guidance on seamless clinical trials for cancer drug developers

7 years ago

Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line

7 years ago

Fresh from hauling in GSK’s budget-priced gene therapy group, Orchard harvests $150M mega-round. Is it time to IPO?

7 years ago

Back to the beginning: Pfizer seeds discovery-stage neuro startup Magnolia (after axing its own brain R&D)

7 years ago

Once stiff-armed at the FDA, new management offers Amicus a warm embrace for Galafold -- priced at $315,000

7 years ago

First page Previous page 1018 1019 102010211022 1023 1024 Next page Last page